Pacira Pharmaceuticals (NASDAQ: PCRX) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.
Valuation & Earnings
This table compares Pacira Pharmaceuticals and AzurRx BioPharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacira Pharmaceuticals||$276.37 million||4.59||-$37.94 million||($1.31)||-23.89|
|AzurRx BioPharma||N/A||N/A||-$14.59 million||N/A||N/A|
Insider and Institutional Ownership
8.4% of AzurRx BioPharma shares are held by institutional investors. 6.6% of Pacira Pharmaceuticals shares are held by insiders. Comparatively, 9.1% of AzurRx BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Pacira Pharmaceuticals and AzurRx BioPharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Pacira Pharmaceuticals has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500.
This is a breakdown of recent ratings for Pacira Pharmaceuticals and AzurRx BioPharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pacira Pharmaceuticals currently has a consensus price target of $46.81, indicating a potential upside of 49.56%. AzurRx BioPharma has a consensus price target of $8.00, indicating a potential upside of 207.69%. Given AzurRx BioPharma’s stronger consensus rating and higher possible upside, analysts plainly believe AzurRx BioPharma is more favorable than Pacira Pharmaceuticals.
AzurRx BioPharma beats Pacira Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.